Retatrutide Dosage Chart: Starting Doses, Titration, and What to Expect

The Triple-Agonist Nobody Told You About

The GLP-1 world moves fast. One year everyone's talking about semaglutide (Ozempic, Wegovy), the next it's tirzepatide (Zepbound, Mounjaro), and now there's a third molecule in the conversation that's producing weight loss numbers that make even the tirzepatide data look modest. It's called retatrutide, and the biohacking crowd is already obsessing over it — which means it's worth cutting through the noise and looking at what the actual clinical research says.

Retatrutide is a triple-receptor agonist: it hits GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors simultaneously. That third receptor is the new piece. Semaglutide hits one. Tirzepatide hits two. Retatrutide hits three. And if you're wondering whether that extra receptor target actually matters, the phase 2 trial data will answer that pretty quickly.

This guide breaks down the retatrutide dosage chart, how titration works, how it compares to semaglutide and tirzepatide, and who this drug might actually make sense for. If you're trying to figure out whether retatrutide is right for your situation, you're in the right place.

What Is Retatrutide, Really?

Retatrutide (development code LY3437943) is an investigational peptide developed by Eli Lilly. It's a once-weekly injectable that targets three metabolic hormone receptors at once: GLP-1, GIP, and glucagon. Think of those three signals as separate levers your body uses to regulate appetite, insulin secretion, and energy expenditure. Semaglutide pulls one lever. Tirzepatide pulls two. Retatrutide pulls all three.

The glucagon piece is the one worth explaining. Glucagon is usually thought of as the hormone that raises blood sugar, which sounds counterproductive for weight loss. But when glucagon receptors are activated in a GLP-1-heavy environment, the effect shifts: it increases energy expenditure, promotes fat burning, and reduces liver fat. You're essentially telling the body to burn harder while simultaneously suppressing appetite and improving insulin sensitivity. That combination is why the weight loss numbers in trials are so striking.

As of 2024, retatrutide is still in clinical trials. It is not yet FDA-approved. That matters a lot for how you interpret dosing information, which we'll get into.

Retatrutide Dosage Chart: What the Phase 2 Trial Used

The most important source for retatrutide dosing is the phase 2 clinical trial published in the New England Journal of Medicine in 2023. Participants were randomized to different doses over a 48-week period, with a structured titration schedule. Here's what the protocol looked like:

Standard Retatrutide Titration Schedule

The trial tested three target maintenance doses: 4 mg, 8 mg, and 12 mg. Each had its own titration pathway leading to those maintenance doses. The 12 mg arm produced the most dramatic results and also the most side effects, which is worth keeping in mind before you go straight for the ceiling.

Retatrutide Dosage by Target Maintenance Dose

That 24.2% figure at 48 weeks is the number that made researchers do a double-take. For context: semaglutide at its highest dose (2.4 mg) produces around 15% weight loss over 68 weeks in the STEP trials. Tirzepatide's best arm hits about 22.5% at 72 weeks. Retatrutide at 12 mg reached 24.2% at just 48 weeks. The trial wasn't long enough to see the plateau, which means the final number could go higher.

How Retatrutide Works: The Triple Mechanism

Ready for some science that won't put you to sleep? The three receptors retatrutide activates each do something different:

• GLP-1 receptor: Slows gastric emptying (you feel full longer), stimulates insulin secretion in response to food, and suppresses appetite via signaling in the brain's hypothalamus. This is the core mechanism of semaglutide.
• GIP receptor: Enhances the insulin response to meals and may reduce some of the nausea side effects of GLP-1 activation alone. This is tirzepatide's second target — and one reason tirzepatide tends to feel more tolerable than semaglutide for many people.
• Glucagon receptor: The new ingredient. In the right hormonal context, glucagon receptor activation raises energy expenditure and promotes fat oxidation (especially in the liver), without spiking blood sugar the way standalone glucagon would.

The combination creates a compound effect: eat less, absorb calories more efficiently, burn more. That's not three effects stacked awkwardly. They interact — and the interaction is what makes the weight loss data so striking.

Here's the catch, though. The glucagon piece also means retatrutide can affect blood glucose in more complex ways than simpler GLP-1 agonists. This is not a drug to self-dose without labs and oversight. The mechanism is sophisticated, and the monitoring needs to match that sophistication.

Retatrutide vs. Semaglutide vs. Tirzepatide: How They Compare

Head-to-head dosage and efficacy comparison

Semaglutide is the proven workhorse. Tirzepatide is the upgrade most people who tolerate GLP-1s well would choose today. Retatrutide looks like the next step — but it's not there yet in terms of regulatory approval, and the long-term safety profile data is still being gathered in phase 3 trials.

What Does the Evidence Actually Show?

The phase 2 trial enrolled 338 adults with obesity (BMI 30 or higher, or 27+ with at least one weight-related comorbidity). After 48 weeks:

• The 12 mg group lost an average of 24.2% of body weight, compared to 2.1% in the placebo group.
• Waist circumference dropped by an average of 18.1 cm in the 12 mg group.
• Fasting insulin, glucose, and lipid markers all improved significantly across dose groups.
• Participants hadn't reached a weight plateau by week 48, suggesting the final weight loss trajectory may be even greater with longer treatment.

A separate phase 2 trial in people with type 2 diabetes showed retatrutide reduced HbA1c (a marker of blood sugar control over time) by up to 2.2 percentage points at the highest dose, with no cases of severe hypoglycemia. That's a meaningful finding for metabolic health, not just weight.

The liver fat data is also notable: significant reductions in hepatic fat fraction were observed, which matters for people with metabolic dysfunction-associated steatotic liver disease (MASLD, formerly called NAFLD).

The Reality Check

Here's what the headlines don't tell you. The phase 2 trial is not a phase 3 trial. It was not designed to establish safety across a broader population or over longer time horizons. The sample was relatively small. We don't have robust data on cardiovascular outcomes the way we do for semaglutide (the SELECT trial) or tirzepatide (the SURMOUNT-4 trial).

Retatrutide is also not FDA-approved. That means if you're accessing it today, you're getting it through compounding pharmacies (where quality and dosing accuracy vary widely) or clinical research settings. That's a meaningful distinction. A compounded product is not the same as a pharmaceutical-grade drug produced under FDA oversight.

The gastrointestinal side effects at high doses are real. Nausea and vomiting rates were substantial in the 12 mg arm. Some participants couldn't reach or sustain the target dose. The trial's dropout rates matter as much as the weight loss numbers, and the two are connected.

Finally: nobody knows what happens when you stop. GLP-1-class drugs generally produce weight regain after discontinuation. Retatrutide will almost certainly follow the same pattern, possibly more dramatically given the magnitude of loss. This is not a course of treatment, it's likely a long-term commitment — if it's right for you at all.

Who Is Retatrutide Actually Right For?

Based on the trial populations and the mechanism, retatrutide makes the most sense if you:

• Have a BMI of 30 or higher, or a BMI of 27+ with metabolic comorbidities (type 2 diabetes, dyslipidemia, hypertension, fatty liver disease)
• Have already tried semaglutide or tirzepatide and found the results insufficient, or you couldn't tolerate them at therapeutic doses
• Are willing to commit to ongoing monitoring: labs, regular check-ins, dose adjustments
• Are working with a clinician who understands the full metabolic picture, not just weight
• Have realistic expectations: this is a long-term metabolic intervention, not a 12-week fix

It's probably not the right starting point if you've never tried a GLP-1 agonist before. Starting with a simpler drug (semaglutide or tirzepatide) and escalating based on response is the more defensible clinical approach right now, given the longer safety track record of those drugs. It's also not the right choice if you're looking for a DTC supplement-style experience. The mechanism is too complex and the monitoring stakes are too high for that.

Risks and Side Effects

The side effect profile of retatrutide is broadly similar to other GLP-1-class drugs, with some nuances from the glucagon component:

• Nausea: Most common, especially during dose escalation. Reported in the majority of participants at higher doses in the phase 2 trial.
• Vomiting and diarrhea: Less common than nausea but significant enough to cause dose reductions or discontinuation in a subset of participants.
• Constipation: The counterintuitive flip side of slowed gastric motility.
• Decreased appetite: This is a feature, but it can tip into inadequate protein and nutrient intake if not managed proactively.
• Potential blood glucose fluctuations: The glucagon component introduces more complexity than a pure GLP-1 agonist. Blood glucose monitoring during titration is important.
• Gallbladder issues: A class-wide concern for rapid weight loss; cholelithiasis (gallstones) risk increases with significant, fast weight reduction.
• Muscle mass loss: A risk with any significant caloric deficit. Adequate protein intake and resistance training are non-negotiable alongside this class of drugs.

The answer to most of these risks is the same: proper clinical supervision, gradual titration, regular labs, and a prescriber who adjusts the protocol based on your individual response. That's not a disclaimer, it's actually how you get the best results.

How to Get Started with Retatrutide Through Healthspan

If you've read this far and you're thinking "this might actually be for me," the next question is how to access it properly. Healthspan's GLP-1 Longevity Care program is built around exactly this kind of nuanced metabolic intervention: not just writing a prescription, but building a full clinical protocol around it.

What that looks like in practice:

• An initial consultation to assess your metabolic baseline, health history, and whether retatrutide, tirzepatide, or semaglutide is the right starting point for you
• Baseline labs covering metabolic markers, liver function, lipids, glucose, and thyroid
• A structured titration schedule tailored to your tolerance — not a one-size-fits-all protocol
• Ongoing check-ins and lab monitoring throughout the titration phase and at maintenance dose
• Guidance on protein intake, muscle preservation, and the lifestyle factors that make GLP-1 therapy actually work long-term
• Dose adjustments based on your response, not just a standard escalation chart

This matters more with retatrutide than with simpler GLP-1 agonists precisely because the triple mechanism is more complex. The glucagon receptor activation, the more aggressive weight loss trajectory, and the more pronounced side effect potential at higher doses all mean this is a drug that requires a prescriber who's paying close attention.

If you're also interested in addressing the metabolic picture more broadly, Healthspan's Metformin and Acarbose protocols are often paired with GLP-1 therapy for people with insulin resistance or blood sugar variability, and the CGM Metabolic Protocol gives you real-time data to understand how your body responds throughout the titration process.

If you're curious whether GLP-1 Longevity Care is right for you, book a consultation and start with your labs. That's the only honest first step.

Frequently Asked Questions About Retatrutide Dosing

What is the starting dose of retatrutide?

In the phase 2 clinical trial, the starting dose of retatrutide was 2 mg once weekly, regardless of the target maintenance dose. This low starting point helps establish tolerance before escalation, minimizing gastrointestinal side effects during the adjustment period.

What is the maximum dose of retatrutide used in trials?

The highest dose tested in the phase 2 trial was 12 mg once weekly. This dose produced the greatest weight loss — approximately 24.2% of body weight at 48 weeks — but also the highest rate of nausea and other GI side effects. Phase 3 trials are evaluating whether this dose-response relationship holds in larger populations.

How long does it take for retatrutide to work?

Meaningful weight loss typically begins within the first 4–8 weeks, but the most significant results accumulate over months. In the phase 2 trial, participants hadn't reached a weight loss plateau by week 48, suggesting the effects compound over time. Expect a slow start during dose titration, with more noticeable changes as you approach and stabilize at your maintenance dose.

Is retatrutide stronger than semaglutide or tirzepatide?

Based on phase 2 data, retatrutide at 12 mg produced greater weight loss (24.2% at 48 weeks) than semaglutide's peak (~15% at 68 weeks) or tirzepatide's peak (~22.5% at 72 weeks). The triple-receptor mechanism appears to drive more significant fat mass reduction and energy expenditure. However, head-to-head trials haven't been published yet, and retatrutide is not FDA-approved.

Can I take retatrutide with metformin or other diabetes medications?

This is a clinical question that requires individual assessment. In the phase 2 trials, some participants with type 2 diabetes were on background medications. The combination of retatrutide with other glucose-lowering drugs requires careful monitoring to avoid hypoglycemia or other interactions. A prescribing clinician should evaluate your full medication list before starting any GLP-1-class drug.

What happens to weight when you stop retatrutide?

Like other GLP-1-class drugs, weight regain after stopping retatrutide is expected. There are no long-term discontinuation studies for retatrutide specifically, but data from semaglutide and tirzepatide show significant regain within 12 months of stopping. This suggests that retatrutide, if effective, is likely a long-term commitment rather than a short course of treatment.

Is retatrutide available without a prescription?

No. Retatrutide is an investigational drug not yet approved by the FDA. Any retatrutide currently accessible outside of clinical trials is being provided through compounding pharmacies, which operate outside FDA pharmaceutical manufacturing standards. Quality, purity, and dosing accuracy can vary significantly. Accessing it through a licensed medical provider with clinical oversight is critical for safety.